Abstract

IntroductionCancer Related Fatigue (CRF) is one of the most common and detrimental side effects of cancer treatment. Despite its increasing prevalence and severity CRF remains dismissed by the majority of clinicians. One reason for the apparent gap between clinical need and clinical undertaking is the penchant toward reductionist accounts of the disorder: a tendency to discount the interface between the lived experience of sufferers and the multi-dimensional etiology of CRF as it manifests adversely on a day-to-day basis.MethodsIn order to better understand the interplay between social, bodily, and emotional components of the disorder we undertook semi-structured interviews with thirteen Breast Cancer survivors suffering from CRF, and then subsequently analyzed their responses using Team Based Qualitative Analysis.ResultsOur analysis revealed multiple dimensions of the social and bodily underpinnings of fatigue. Most relevantly we found a consistent change in the level and quality of attention to bodily signals. This shift in awareness appeared to be directly connected to the experience of CRF and a newfound, “respect,” for the needs of the body. Furthermore, we found that many of the practices that were described as helpful in alleviating fatigue were oriented around eliciting a sense of embodied awareness, examples being: dance, yoga, and shamanic ritual. This relationship with bodily sensations existed in conjunction with the anxiety and trauma that arose as a result of cancer treatment.ConclusionOur analysis suggests that the quality of awareness and relationship to bodily experience in CRF is a functionally relevant component of the disorder and should be considered as an experiential target moving forward.

Highlights

  • Cancer Related Fatigue (CRF) is one of the most common and detrimental side effects of cancer treatment

  • Cancer-related fatigue (CRF) commonly accompanies Cancer and has been defined as, “a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning” (Berger et al, 2015)

  • It is estimated that 39% of individuals will be diagnosed with some form of cancer over the course of their lifetime (Howlader et al, 2016). For many of these persons the burden of disease will not end after treatment, but will continue to manifest as a host of factors that impair quality of life (QOL), and catalyze subsequent pathologies (Curt et al, 2000; Holley, 2000; Kurzrock, 2001; Schultz et al, 2003; Yabroff et al, 2004; Mustian et al, 2007; Roscoe et al, 2007; Bower, 2008; Brown and Kroenke, 2009; Saligan et al, 2015; Antoni et al, 2016)

Read more

Summary

Introduction

Cancer Related Fatigue (CRF) is one of the most common and detrimental side effects of cancer treatment. It is estimated that 39% of individuals will be diagnosed with some form of cancer over the course of their lifetime (Howlader et al, 2016) For many of these persons the burden of disease will not end after treatment, but will continue to manifest as a host of factors that impair quality of life (QOL), and catalyze subsequent pathologies (Curt et al, 2000; Holley, 2000; Kurzrock, 2001; Schultz et al, 2003; Yabroff et al, 2004; Mustian et al, 2007; Roscoe et al, 2007; Bower, 2008; Brown and Kroenke, 2009; Saligan et al, 2015; Antoni et al, 2016).

Objectives
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.